Adaptimmune Therapeutics (ADAP) Tops Q2 EPS by 16c

Adaptimmune Therapeutics (NASDAQ: ADAP) reported Q2 EPS of ($0.02), $0.16 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $5.13 million versus the consensus estimate of $9.25 million.

For earnings history and earnings-related data on Adaptimmune Therapeutics (ADAP) click here.

You May Also Be Interested In

• SpaceX: New Street Research sees 22% upside from proposed IPO price
• Vera Bradley (VRA) Misses Q1 EPS by 26c ; Offers Guidance
• Morgan Stanley Upgrades Towa Pharmaceutical Co Ltd (4553:JP) to Overweight